Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 24 of 24

TitleReference numberPublishedLast updated
Brolucizumab for treating diabetic macular oedemaTA820
Faecal microbiota transplant for recurrent Clostridioides difficile infectionHTG638
Contrast-enhanced spectral mammography for breast cancerMIB304
Differential target multiplexed spinal cord stimulation for chronic lower back and leg painMIB305
iFuse for treating chronic sacroiliac joint painHTG488
Avalglucosidase alfa for treating Pompe diseaseTA821
Transcutaneous electrical neuromuscular stimulation for urinary incontinenceHTG636
Superficial venous arterialisation for chronic limb threatening ischaemiaHTG637
Focal resurfacing implants to treat articular cartilage damage in the kneeHTG635
Type 1 diabetes in adults: diagnosis and managementNG17
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesotheliomaTA818
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infectionsAMR1
Cefiderocol for treating severe drug-resistant gram-negative bacterial infectionsAMR2
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrenceTA817
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDsTA815
SecurAcath for securing percutaneous cathetersHTG440
Stockholm3 for prostate cancer screeningMIB303
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancerTA812
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitorsTA813
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitisTA814
Bioresorbable stent implantation to treat coronary artery diseaseHTG633
Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissectionHTG634

Results per page

  1. 10
  2. 25
  3. 50
  4. All